https://scholars.lib.ntu.edu.tw/handle/123456789/468748
標題: | Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin | 作者: | YEUN-CHUNG CHANG CHONG-JEN YU CHUNG-MING CHEN Hu F.-C. Hsu H.-H. WEN-YIH TSENG TIFFANY TING-FANG SHIH PAN-CHYR YANG Chih-Hsin CHIH-HSIN YANG |
公開日期: | 2012 | 卷: | 36 | 期: | 2 | 起(迄)頁: | 387-396 | 來源出版物: | Journal of Magnetic Resonance Imaging | 摘要: | Purpose: To investigate dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) of advanced nonsmall-cell lung cancer (NSCLC) patients treated with the antiangiogenic agent bevacizumab combined with gemcitabine and cisplatin as first-line treatment. Materials and Methods: All patients were enrolled for MRI and computed tomography (CT) before and after the first three courses of bevacizumab combination chemotherapy. Pharmacokinetic parameters (Ktrans, kep, ve, vp) derived from DCE MRI were computed for the main mass. Parametric histogram analysis was obtained to evaluate changes of the internal tumor composition and for correlation with tumor response measured on CT. Results: After three cycles of treatment, 11 patients showed decreased tumor size and a decreased value of all MR-derived pharmacokinetic parameters. Among these parameters, there was a significant decrease of mean and standard deviation of the Ktrans histogram as well as a decrease of mean of the kep histogram (P < 0.05). Tumors with larger mean values of rate constant kep (P < 0.0001) and smaller standard deviation of volume of extravascular extracellular space fraction ve (P < 0.0001) on histograms before chemotherapy were considered predictors for treatment response. Conclusion: DCE MRI enables a functional analysis of the treatment response of NSCLC. MRI parametric histogram has the potential to predict early treatment response of combined bevacizumab, gemcitabine, and cisplatin. Copyright ? 2012 Wiley Periodicals, Inc. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84864272568&doi=10.1002%2fjmri.23660&partnerID=40&md5=6bc33129246b689f31dba083e2ff1629 https://scholars.lib.ntu.edu.tw/handle/123456789/468748 |
ISSN: | 1053-1807 | DOI: | 10.1002/jmri.23660 | SDG/關鍵字: | bevacizumab; cisplatin; gemcitabine; adult; advanced cancer; aged; article; clinical article; computer assisted tomography; contrast enhancement; dynamic contrast enhanced magnetic resonance imaging; female; histogram; human; image analysis; lung non small cell cancer; male; multiple cycle treatment; nuclear magnetic resonance imaging; priority journal; treatment response; tumor volume; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Contrast Media; Deoxycytidine; Female; Gadolinium DTPA; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome |
顯示於: | 醫療器材與醫學影像研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。